Form 8-K Valeant Pharmaceuticals For: Apr 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Valeant Pharma (VRX) Short Interest Surges 56% - Guggenheim
April 11, 2016 5:42 PM EDTIn analyzing the latest short interest data for the Specialty Pharmaceutical sector, Guggenheim's Louise Chen notes that Valeant Pharma (NYSE: VRX) short interest rose 56.1% - the largest increase in the sector.
Valeant Pharma short interest was at 18,021,306 shares as of 03/31/2016, versus 11,548,303... More
Valeant (VRX) Enters Amended Credit Agreement; Extends Date of 10-K Filing, Waives Cross-Default
April 11, 2016 4:28 PM EDTValeant Pharma (NYSE: VRX) disclosed the following on Monday:
Item 1.01. Entry Into a Material Definitive Agreement.
On April 11, 2016, Valeant Pharmaceuticals International, Inc. (the Company) entered into an amendment and waiver (Amendment No. 12) to its Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the Credit Agreement).
Amendment No. 12 extends the deadline for filing (i) the Companys Form 10-K for the fiscal year ended December 31, 2015 to May 31, 2016 and (ii) the Companys Form 10-Q for the... More
